Elevance Health, Inc. (ELV) fair value analysis
S&P 500 · Updated 2026-09-07
Elevance Health, Inc. is a health insurance company that provides medical, dental, and vision insurance coverage to individuals and groups. The company operates across the United States through various insurance brands and serves customers in all 50 states.
Forward Fair Value verdict
Fairly valuedBased on TickrTrends' weekly Forward Fair Value model, ELV is trading at within about 10% of estimated fair value.
ELV currently ranks #74 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.
- Last price
- $407.50
- Sector
- Healthcare
- 12-month range
- $294.07–$403.04
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Moderate
- Margin trend
- Stable
- Revenue growth
- Modest
- RSI zone
- Neutral
- 52-week position
- The top quarter of its range
- DCF cross-check
- Fairly Valued
What our data shows for ELV
- Our model validated 17 trailing price-to-earnings windows for ELV, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $294.07–$403.04.
- The 14-day relative strength index sits at a neutral 59.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ELV
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
What people are saying
Follow the ELV conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — ELV's valuation assessment improved this week as TickrTrends' DCF cross-check band shifted from overvalued to fairly valued. The Healthcare sector stock now carries a fairly valued verdict based on the latest derived indicators. This change suggests the stock's price has moved into closer alignment with its fundamental value estimates.
- 2026-09-06 — TickrTrends' derived indicators for ELV showed a significant shift this week, with the DCF cross-check band moving from an undervalued assessment to an overvalued one. This change suggests that the company's valuation has moved beyond fair value based on discounted cash flow analysis. The current valuation verdict remains fairly valued according to TickrTrends' overall assessment despite this movement in the DCF cross-check band.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ELV stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), ELV is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is ELV's TickrTrends verdict?
ELV's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does ELV compare to other Healthcare stocks?
ELV ranks #74 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.
Is ELV overbought or oversold?
ELV's 14-day RSI is in neutral territory - neither overbought nor oversold.
More in Healthcare
Head-to-head comparisons
ELV vs ACHC · ELV vs AZTA · ELV vs COR · ELV vs HCSG · ELV vs HSIC